title: FDG-PET adapted sequential therapy with brentuximab vedotin and augmented ICE followed by autologous stem cell transplant for relapsed and refractory Hodgkin lymphoma.
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D064592:Autografts; D000079963:Brentuximab Vedotin; D002945:Cisplatin / Q000008:administration & dosage; D018572:Disease-Free Survival; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006689:Hodgkin Disease / Q000000981:diagnostic imaging / Q000401:mortality / Q000628:therapy; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D018796:Immunoconjugates / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography; D011859:Radiography; D012008:Recurrence; D033581:Stem Cell Transplantation; D015996:Survival Rate
chemical_list: D018796:Immunoconjugates; D005047:Etoposide; D000079963:Brentuximab Vedotin; D002945:Cisplatin; D007069:Ifosfamide